IL311751A - IL-17 imidazopyridazine inhibitory compounds - Google Patents
IL-17 imidazopyridazine inhibitory compoundsInfo
- Publication number
- IL311751A IL311751A IL311751A IL31175124A IL311751A IL 311751 A IL311751 A IL 311751A IL 311751 A IL311751 A IL 311751A IL 31175124 A IL31175124 A IL 31175124A IL 311751 A IL311751 A IL 311751A
- Authority
- IL
- Israel
- Prior art keywords
- alkyl
- cycloalkyl
- compound
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163248566P | 2021-09-27 | 2021-09-27 | |
| US202163273422P | 2021-10-29 | 2021-10-29 | |
| US202263367546P | 2022-07-01 | 2022-07-01 | |
| PCT/US2022/077001 WO2023049887A1 (en) | 2021-09-27 | 2022-09-26 | Imidazopyridazine il-17 inhibitor compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL311751A true IL311751A (en) | 2024-05-01 |
Family
ID=83692741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL311751A IL311751A (en) | 2021-09-27 | 2022-09-26 | IL-17 imidazopyridazine inhibitory compounds |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US12173007B2 (https=) |
| EP (1) | EP4408847A1 (https=) |
| JP (1) | JP2024536869A (https=) |
| KR (1) | KR20240082369A (https=) |
| AU (1) | AU2022349687A1 (https=) |
| CA (1) | CA3233408A1 (https=) |
| CL (1) | CL2024000867A1 (https=) |
| CO (1) | CO2024003723A2 (https=) |
| DO (1) | DOP2024000051A (https=) |
| IL (1) | IL311751A (https=) |
| JO (1) | JOP20240059A1 (https=) |
| MX (1) | MX2024003772A (https=) |
| PE (1) | PE20240935A1 (https=) |
| TW (1) | TW202330530A (https=) |
| UY (1) | UY39958A (https=) |
| WO (1) | WO2023049887A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL311751A (en) | 2021-09-27 | 2024-05-01 | Janssen Pharmaceutica Nv | IL-17 imidazopyridazine inhibitory compounds |
| CN118401519A (zh) | 2021-10-25 | 2024-07-26 | 拓臻制药公司 | 作为glp-1r激动剂的化合物 |
| TW202430165A (zh) | 2022-12-02 | 2024-08-01 | 丹麥商理奧藥品公司 | Il-17之小分子調節劑 |
| CN120731202A (zh) * | 2023-01-30 | 2025-09-30 | 戴斯阿尔法公司 | 基于苯并咪唑和氮杂-苯并咪唑的il-17a调节剂及其用途 |
| CN121311483A (zh) * | 2023-03-28 | 2026-01-09 | 詹森药业有限公司 | 含内酰胺的咪唑并哒嗪il-17抑制剂化合物 |
| EP4568664B1 (en) | 2023-04-07 | 2026-04-01 | Terns Pharmaceuticals, Inc. | Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating obesity |
| WO2024215597A1 (en) * | 2023-04-11 | 2024-10-17 | Dice Alpha, Inc. | Substituted 6-imidazopyridazine il-17a modulators and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI752400B (zh) | 2019-01-07 | 2022-01-11 | 美商美國禮來大藥廠 | Il-17a抑制劑 |
| GB201909190D0 (en) | 2019-06-26 | 2019-08-07 | Ucb Biopharma Sprl | Therapeutic agents |
| PE20230469A1 (es) | 2020-04-30 | 2023-03-14 | Janssen Pharmaceutica Nv | Imidazopiridazinas como moduladores de il-17 |
| WO2023025783A1 (en) | 2021-08-23 | 2023-03-02 | Leo Pharma A/S | Small molecule modulators of il-17 |
| IL311751A (en) | 2021-09-27 | 2024-05-01 | Janssen Pharmaceutica Nv | IL-17 imidazopyridazine inhibitory compounds |
| CN116143777A (zh) | 2021-11-04 | 2023-05-23 | 四川海思科制药有限公司 | 一种可抑制il-17a的杂环化合物及其用途 |
-
2022
- 2022-09-26 IL IL311751A patent/IL311751A/en unknown
- 2022-09-26 WO PCT/US2022/077001 patent/WO2023049887A1/en not_active Ceased
- 2022-09-26 TW TW111136301A patent/TW202330530A/zh unknown
- 2022-09-26 PE PE2024000594A patent/PE20240935A1/es unknown
- 2022-09-26 EP EP22790174.1A patent/EP4408847A1/en active Pending
- 2022-09-26 CA CA3233408A patent/CA3233408A1/en active Pending
- 2022-09-26 UY UY0001039958A patent/UY39958A/es unknown
- 2022-09-26 US US17/935,360 patent/US12173007B2/en active Active
- 2022-09-26 KR KR1020247013352A patent/KR20240082369A/ko active Pending
- 2022-09-26 AU AU2022349687A patent/AU2022349687A1/en active Pending
- 2022-09-26 MX MX2024003772A patent/MX2024003772A/es unknown
- 2022-09-26 JP JP2024518884A patent/JP2024536869A/ja active Pending
-
2024
- 2024-03-14 DO DO2024000051A patent/DOP2024000051A/es unknown
- 2024-03-22 CO CONC2024/0003723A patent/CO2024003723A2/es unknown
- 2024-03-25 CL CL2024000867A patent/CL2024000867A1/es unknown
- 2024-03-26 JO JOJO/P/2024/0059A patent/JOP20240059A1/ar unknown
- 2024-10-04 US US18/906,207 patent/US20250109137A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230143050A1 (en) | 2023-05-11 |
| CL2024000867A1 (es) | 2024-09-23 |
| CO2024003723A2 (es) | 2024-04-18 |
| WO2023049887A1 (en) | 2023-03-30 |
| AU2022349687A1 (en) | 2024-05-16 |
| EP4408847A1 (en) | 2024-08-07 |
| PE20240935A1 (es) | 2024-04-30 |
| CA3233408A1 (en) | 2023-03-30 |
| MX2024003772A (es) | 2024-06-19 |
| US12173007B2 (en) | 2024-12-24 |
| US20250109137A1 (en) | 2025-04-03 |
| TW202330530A (zh) | 2023-08-01 |
| KR20240082369A (ko) | 2024-06-10 |
| JOP20240059A1 (ar) | 2024-03-26 |
| JP2024536869A (ja) | 2024-10-08 |
| DOP2024000051A (es) | 2024-11-15 |
| UY39958A (es) | 2023-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL311751A (en) | IL-17 imidazopyridazine inhibitory compounds | |
| JP2013533884A5 (https=) | ||
| AU2012255759C1 (en) | Kinase inhibitors | |
| JP2024536869A5 (https=) | ||
| EP1458722B1 (de) | Pyrrolopyrimidine als phosphodiesterase-vii-hemmer | |
| AU2020412853A1 (en) | Carboxy derivatives with antiinflammatory properties | |
| JP2024536863A5 (https=) | ||
| EP2044023A1 (en) | Derivatives of 1-phenyl-2-pyridynyl alkylene alcohols as phosphodiesterase inhibitors | |
| US12459908B2 (en) | Alpha, beta unsaturated methacrylic esters with anti-inflammatory properties | |
| CN115667239A (zh) | 取代吡嗪类化合物，包含其的药物组合物及其用途 | |
| HRP20211973T1 (hr) | Kinazolini kao inhibitori ionskih kalijskih kanala | |
| IL256433A (en) | Cot modulators and methods for using them | |
| JP2013533883A5 (https=) | ||
| JP2018529762A5 (https=) | ||
| CA2648036A1 (en) | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine h4 receptor | |
| JP2013530238A5 (https=) | ||
| JP2018520161A5 (https=) | ||
| JP2009534407A5 (https=) | ||
| JP2017534591A5 (https=) | ||
| JP2012521994A5 (https=) | ||
| JP2015518902A5 (https=) | ||
| JP2019533714A5 (https=) | ||
| JP2013522316A5 (https=) | ||
| JP2018510131A5 (https=) | ||
| PE20212197A1 (es) | Formas de sal y cristalinas de un compuesto organico y composiciones farmaceuticas del mismo |